News >

EU Prescribing Patterns for Rituximab Biosimilars in Non-Hodgkin Lymphoma

Jason M. Broderick @jasoncology
Published: Thursday, Jun 28, 2018

Dr. European patients with non-Hodgkin lymphoma (NHL) are more likely to be prescribed a rituximab (MabThera, EU; Rituxan, US) biosimilar if they are in better overall health, have indolent histology, and have follicular lymphoma, according to a study presented at the 2018 ASCO Annual Meeting.

Franceschetti A, Caldeira R. Treatment approach for non-Hodgkin lymphoma patients since first biosimilars of rituximab approved in EU5. J Clin Oncol. 2018;36 (suppl; abstr 112).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Publication Bottom Border
Border Publication